Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Xconomy
SEPTEMBER 18, 2020
Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. This week, it made its biggest buy yet.
67 
Let's personalize your content